Two different schedules for integrating filgrastim as adjuvant therapy in the treatment of patients with advanced stage Hodgkin's lymphoma receiving MOPP/ABV hybrid chemotherapy
Autor: | Guy Cantin, Gyger M, Linda Lacroix, Bernard Lespérance, Pierre A. Ouellet, L. Arthur Hewitt, Marc Bergeron, Félix Couture, Daniel Bélanger, Lidia Pirc, Louis Desjardins, Louise Yelle, Jean Dufresne |
---|---|
Rok vydání: | 1999 |
Předmět: |
Adult
Male Oncology Cancer Research Vincristine medicine.medical_specialty Adolescent Filgrastim Neutropenia Toxicology Procarbazine Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Adjuvant therapy Humans Pharmacology (medical) Mechlorethamine Neoplasm Staging Pharmacology business.industry Middle Aged medicine.disease Hodgkin's lymphoma Hodgkin Disease Recombinant Proteins Surgery Granulocyte colony-stimulating factor Regimen Prednisone Female business medicine.drug |
Zdroj: | Cancer Chemotherapy and Pharmacology. 43:503-506 |
ISSN: | 1432-0843 0344-5704 |
DOI: | 10.1007/s002800050930 |
Popis: | Purpose: Management of advanced-stage Hodgkin's disease with a MOPP/ABV hybrid regimen (mechlorethamine, vincristine, procarbazine, prednisone, Adriamycin, bleomycin and vinblastine) has yielded a high complete response rate (75–85%). However, myelosuppression can limit delivery of treatment. Filgrastim has been shown to reduce chemotherapy-related neutropenia and allow for on-time administration of planned doses of chemotherapeutic agents. The objective of this study was to find the best way to integrate filgrastim with the MOPP/ABV hybrid regimen. Methods: Enrolled in this study were 24 patients (aged 18–52 years) with newly diagnosed, histologically documented Hodgkin's disease. In schedule I, patients received filgrastim (5 μg/kg s.c. daily) beginning on day 9, 24 h after administration of ABV. In schedule II, patients received filgrastim concomitantly with procarbazine on days 2–7 (starting 24 h after day-1 MOPP administration and stopping 24 h before ABV administration) as well as after ABV beginning on day 9. Filgrastim after ABV administration was administered until two consecutive ANC readings of 10 × 109/l were achieved. Results: All patients were able to complete all six cycles of therapy. There was a trend to fewer dose reductions in schedule II (0.76%) as compared to schedule I (4.2%) with a P-value of 0.077 (chi-squared test). Specifically, 11.6% of MOPP courses and 5.5% of ABV courses were dose-reduced in schedule I versus 1.7% and 1.4%, respectively, in schedule II. Conclusion: In conclusion, filgrastim was effective in supporting the delivery of the MOPP/ABV chemotherapy. Concomitant administration of filgrastim with procarbazine (days 2–7) appears to be safe and allows the maximum dose intensity of this therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |